Literature DB >> 18470643

PEGylated adenovirus for targeted gene therapy.

Catherine R O'Riordan1, Antonius Song.   

Abstract

Bifunctional polyethylene glycol (PEG) molecules provide a novel approach to retargeting viral vectors without the need to genetically modify the vector. Modification of the surface of adenovirus with heterofunctional PEG allows further modification of the capsid with ligands. In addition, heterofunctional PEG modification ablates the normal tropism of the virus and reduces transduction of non-target tissues in vivo. Moreover, the addition of PEG chains to the surface of the virus shields antigen-binding sites, significantly reducing the susceptibility of the virus to antibody neutralization. Finally, T cell subsets from mice exposed to the PEGylated vector demonstrate a marked decrease in Th1 and Th2 responses, suggesting that PEG modification may help reduce the immune response to the vector.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18470643     DOI: 10.1007/978-1-60327-248-3_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

Review 1.  Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Authors:  Erin E Thacker; Laura Timares; Qiana L Matthews
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

2.  Display of DNA on Nanoparticles for Targeting Antigen Presenting Cells.

Authors:  Nicholas M Molino; Medea Neek; Jo Anne Tucker; Edward L Nelson; Szu-Wen Wang
Journal:  ACS Biomater Sci Eng       Date:  2017-03-14

3.  Increasing the efficacy of oncolytic adenovirus vectors.

Authors:  Karoly Toth; William S M Wold
Journal:  Viruses       Date:  2010-08-27       Impact factor: 5.818

4.  PEGylated Adenoviruses: From Mice to Monkeys.

Authors:  Piyanuch Wonganan; Maria A Croyle
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.818

Review 5.  Current progress in the development of a prophylactic vaccine for HIV-1.

Authors:  Lena J Gamble; Qiana L Matthews
Journal:  Drug Des Devel Ther       Date:  2010-12-22       Impact factor: 4.162

Review 6.  Designer Oncolytic Adenovirus: Coming of Age.

Authors:  Alexander T Baker; Carmen Aguirre-Hernández; Gunnel Halldén; Alan L Parker
Journal:  Cancers (Basel)       Date:  2018-06-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.